← Eichor
Condition: Relapsed Or Refractory B Cell Acute Lymphoblastic Leukemia Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Relapsed Or Refractory B Cell Acute Lymphoblastic Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Phase 1 · 31 location(s) · Therapeutic Advances in Childhood Leukemia Consortium · NCT05476770A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Phase 2/Phase 3 · 12 location(s) · Merck Sharp & Dohme LLC · NCT07570173JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
NA · 1 location(s) · Affiliated Hospital of Guangdong Medical University · NCT06940960Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic
Phase 1 · 8 location(s) · Autolus Limited · NCT06173518Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.
EARLY_Phase 1 · 1 location(s) · Tan Jie · NCT06659653Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Phase 1/Phase 2 · 19 location(s) · Cellectis S.A. · NCT04150497A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04532281A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relap
Phase 1 · 8 location(s) · Shanghai Pharmaceutical Group Biological Therapy Technology · NCT06927466Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL
Phase 1/Phase 2 · 1 location(s) · Kara Yakhteh Tajhiz Azma Company · NCT06635330Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignanci
Phase 1 · 1 location(s) · University of Kansas Medical Center · NCT06879340UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
Phase 1/Phase 2 · 1 location(s) · University of Colorado, Denver · NCT04544592CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04603872CAR-T Cell Therapy for ALL
EARLY_Phase 1 · 1 location(s) · Dr. Zaineb Akram · NCT07695012AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Phase 1/Phase 2 · 80 location(s) · AstraZeneca · NCT06137118A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06287528Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia
Phase 1/Phase 2 · 11 location(s) · University Hospital Tuebingen · NCT05366218Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients
Phase 1/Phase 2 · 2 location(s) · Curocell Inc. · NCT04836507Co-administration of CART22-65s and huCART19 for B-ALL
Phase 1/Phase 2 · 1 location(s) · Stephan Grupp MD PhD · NCT05674175Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523555CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
Phase 1 · 2 location(s) · Rong Tao · NCT06445803Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r
Phase 1 · 23 location(s) · Imugene Limited · NCT03666000Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
Phase 1 · 1 location(s) · Belarusian Research Center for Pediatric Oncology, Hematolog · NCT05333302Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or
EARLY_Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT04512716A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Maligna
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04532203Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT07429461JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
NA · 1 location(s) · Tongji Hospital · NCT06689917CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma
Phase 1 · 1 location(s) · Institute of Hematology and Blood Transfusion, Czech Republi · NCT05054257CD-19 CAR-T Cell for Pediatric ALL or Lymphoma
NA · 1 location(s) · Hong Kong Children's Hospital · NCT06866873Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, o
Phase 2 · 278 location(s) · National Cancer Institute (NCI) · NCT03739814
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.